Differential early subcortical involvement in genetic FTD within the GENFI cohort. by Bocchetta, Martina et al.
NeuroImage: Clinical 30 (2021) 102646
Available online 29 March 2021
2213-1582/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Differential early subcortical involvement in genetic FTD within the 
GENFI cohort 
Martina Bocchetta a, Emily G. Todd a, Georgia Peakman a, David M. Cash a,b, Rhian S. Convery a, 
Lucy L. Russell a, David L. Thomas a,c, Juan Eugenio Iglesias b,d,e, John C. van Swieten f, 
Lize C. Jiskoot f, Harro Seelaar f, Barbara Borroni g, Daniela Galimberti h,i, 
Raquel Sanchez-Valle j, Robert Laforce Jr k, Fermin Moreno l, Matthis Synofzik m, 
Caroline Graff n,o, Mario Masellis p, Maria Carmela Tartaglia q, James B. Rowe r, 
Rik Vandenberghe s, Elizabeth Finger t, Fabrizio Tagliavini u, Alexandre de Mendonça v, 
Isabel Santana w, Chris R. Butler x, Simon Ducharme y, Alexander Gerhard z,aa, Adrian Danek ab, 
Johannes Levin ab, Markus Otto ac, Sandro Sorbi ad, Isabelle Le Ber ae,af,ag, 
Florence Pasquier ah,ai,aj, Jonathan D. Rohrer a,*, on behalf of the Genetic Frontotemporal 
dementia Initiative (GENFI) 
a Instituto Ciencias Nucleares Aplicadas a Saude, Universidade de Coimbra, Coimbra, Portugal 
b Faculty of Medicine, University of Coimbra, Coimbra, Portugal 
c Department of Neurology, University of Ulm, Ulm, Germany 
d Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden 
e Alzheimer’s disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain 
f Biotechnology Laboratory, Department of Diagnostics, ASST Brescia Hospital, Brescia, Italy 
g Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy, University of Milan, Centro Dino Ferrari, Milan, Italy 
h Alzheimer’s disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain 
i Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain, euroscience Area, Biodonostia Health Research 
Institute, San Sebastian, Gipuzkoa, Spain 
j Imaging Diagnostic Center, Hospital Clínic, Barcelona, Spain 
k Department of Medical Biophysics, The University of Western Ontario, London, Ontario, Canada, Centre for Functional and Metabolic Mapping, Robarts Research 
Institute, The University of Western Ontario, London, Ontario, Canada 
l Department of Diagnostic and Interventional Neuroradiology, University of Tübingen, Tübingen, Germany 
m Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Italy 
n Inserm 1172, Lille, France, CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, France 
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A B S T R A C T   
Background: Studies have previously shown evidence for presymptomatic cortical atrophy in genetic FTD. Whilst 
initial investigations have also identified early deep grey matter volume loss, little is known about the extent of 
subcortical involvement, particularly within subregions, and how this differs between genetic groups. 
Methods: 480 mutation carriers from the Genetic FTD Initiative (GENFI) were included (198 GRN, 202 C9orf72, 
80 MAPT), together with 298 non-carrier cognitively normal controls. Cortical and subcortical volumes of in-
terest were generated using automated parcellation methods on volumetric 3 T T1-weighted MRI scans. Mutation 
carriers were divided into three disease stages based on their global CDR® plus NACC FTLD score: asymptomatic 
(0), possibly or mildly symptomatic (0.5) and fully symptomatic (1 or more). 
Results: In all three groups, subcortical involvement was seen at the CDR 0.5 stage prior to phenoconversion, 
whereas in the C9orf72 and MAPT mutation carriers there was also involvement at the CDR 0 stage. In the 
C9orf72 expansion carriers the earliest volume changes were in thalamic subnuclei (particularly pulvinar and 
lateral geniculate, 9–10%) cerebellum (lobules VIIa-Crus II and VIIIb, 2–3%), hippocampus (particularly pre-
subiculum and CA1, 2–3%), amygdala (all subregions, 2–6%) and hypothalamus (superior tuberal region, 1%). In 
MAPT mutation carriers changes were seen at CDR 0 in the hippocampus (subiculum, presubiculum and tail, 
3–4%) and amygdala (accessory basal and superficial nuclei, 2–4%). GRN mutation carriers showed subcortical 
differences at CDR 0.5 in the presubiculum of the hippocampus (8%). 
Conclusions: C9orf72 expansion carriers show the earliest and most widespread changes including the thalamus, 
basal ganglia and medial temporal lobe. By investigating individual subregions, changes can also be seen at CDR 
0 in MAPT mutation carriers within the limbic system. Our results suggest that subcortical brain volumes may be 
used as markers of neurodegeneration even prior to the onset of prodromal symptoms.   
1. Introduction 
Frontotemporal dementia (FTD) is a common cause of early onset 
dementia. In about a third of the cases it is associated with an autosomal 
dominant inherited mutation in one of three genes: microtubule- 
associated protein tau (MAPT), progranulin (GRN), and chromosome 9 
open reading frame 72 (C9orf72) (Warren et al., 2013). For each of these 
genetic groups, there is evidence of a differential pattern of cortical at-
rophy (Chen and Kantarci, 2020), with changes occurring pre-
symptomatically, up to twenty years before estimated phenoconversion 
(Rohrer et al., 2015; Cash et al., 2018). Whilst these studies have been 
highly informative in describing the presence of brain changes in pre-
symptomatic stages of the disease, they have focused less on subcortical 
structures, and in particular, they have not investigated specific sub-
regions within the deep grey matter. However, due to advanced imaging 
methods, it is now possible to measure these individual nuclei and 
subregions in vivo on structural magnetic resonance scans, with prior 
studies in small cohorts showing changes at the symptomatic stage of 
genetic FTD (Bocchetta et al., 2016, 2018, 2019, 2020), but without any 
previous investigation of the presymptomatic period. Using data from 
the Genetic FTD Initiative (GENFI) cohort, we therefore aimed to 
examine the specific pattern of subcortical changes (including specific 
subregions), to determine which areas were impaired across the 
different disease stages of genetic FTD. 
2. Methods 
At the time of the fifth data freeze in the GENFI 2 study (03/03/ 
2015–31/05/2019), 850 participants had been recruited across 24 
centres in the United Kingdom, Canada, Italy, the Netherlands, Sweden, 
Portugal, Germany, France, Spain, and Belgium, of whom 804 had a 
volumetric T1-weighted magnetic resonance image acquired on a 3 T 
scanner. Another 26 participants were excluded as the scans were of 
unsuitable quality due to motion or other imaging artefacts, pathology 
unlikely to be attributed to FTD, or as they were carriers of mutations in 
one of the rarer genetic causes of FTD. All the remaining 778 partici-
pants were known to be either a carrier of a pathogenic expansion in 
C9orf72 or of a pathogenic mutation in GRN or MAPT (n = 480), or were 
non-carrier first-degree relatives (n = 298), who therefore acted as 
controls within the study. All aspects of the study were approved by the 
local ethics committee for each of the GENFI sites, and written informed 
consent was obtained from all participants. 
All participants underwent a standardized clinical assessment as 
described previously (Rohrer et al., 2015). This included the CDR® plus 
NACC FTLD (Miyagawa et al., 2020) which was used to group the mu-
tation carriers into stages: those with a global score of 0 were considered 
as asymptomatic, those with a score of 0.5 considered as possibly or 
mildly symptomatic (i.e. prodromal), and those with a score ≥ 1 were 
considered as fully symptomatic or phenoconverted (Table 1). 
Participants underwent a 1.1-mm isotropic resolution volumetric T1- 
weighted magnetic resonance imaging (MRI) on a 3 T scanner (Siemens 
Trio, Siemens Skyra, Siemens Prisma, Philips Achieva, GE Discovery 
MR750). Volumetric MRI scans were first bias field corrected and whole 
brain parcellated using the geodesic information flow (GIF) algorithm 
(Cardoso et al., 2015), which is based on atlas propagation and label 
fusion. We combined regions of interest to calculate grey matter vol-
umes of the cortex for 15 regions: orbitofrontal, dorsolateral (DLPFC) 
and ventromedial prefrontal, motor, anterior and posterior insula, 
temporal pole, dorsolateral and medial temporal, anterior and posterior 
cingulate, sensory, medial and lateral parietal, and occipital cortex. 
Using GIF and customised versions of specific Freesurfer modules 
(Iglesias et al., 2015a, 2015b, 2018; Saygin et al., 2017) that accept the 
GIF parcellation as inputs (Bocchetta et al., 2020, 2018, 2019, 2020a) 
we also calculated individual volumes for the following subcortical re-
gions (Fig. 1): i) basal ganglia (nucleus accumbens, caudate, putamen, 
and globus pallidus, ii) basal forebrain, iii) amygdala (5 regions: lateral 
nucleus, basal and paralaminar nucleus, accessory basal nucleus, 
cortico-amygdaloid transition area and the superficial nuclei), iv) hip-
pocampus (7 regions: cornu ammonis CA1, CA2/CA3, CA4, dentate 
gyrus, subiculum, presubiculum, tail), v) thalamus (14 regions: 
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anteroventral, laterodorsal (LD), lateral posterior, ventral anterior, 
ventral lateral anterior, ventral lateral posterior, ventral posterolateral, 
ventromedial, intralaminar, midline, mediodorsal (MD), lateral genic-
ulate (LGN), medial geniculate (MGN) and pulvinar). Volumes for the 
hypothalamus (5 regions: anterior superior, anterior inferior, superior 
tuberal (s-tub), inferior tuberal (i-tub), posterior) were computed using 
the deep convolutional neural network method described in (Billot et al., 
2020). We also parcellated the cerebellum (separated into 14 regions: 
lobules I-IV, V, VI, VIIa-Crus I, VIIa-Crus II, VIIb, VIIIa, VIIIb, IX, X, 
vermis, dentate nucleus, interposed nucleus and fastigial nucleus (Die-
drichsen et al., 2009, 2011), and brainstem (superior cerebellar 
peduncle, medulla, pons, and midbrain). 
Left and right volumes were summed, and total intracranial volume 
was computed with SPM12 v6470 (Statistical Parametric Mapping, 
Wellcome Trust Centre for Neuroimaging, London, UK) running under 
Matlab R2014b (Math Works, Natick, MA, USA) (Malone et al., 2015). 
All segmentations were visually checked for quality with only one sub-
ject excluded from the cerebellar analyses due to the presence of an 
arachnoid cyst. Statistical analyses were performed in SPSS software 
(SPSS Inc., Chicago, IL, USA) version 26, with a linear regression anal-
ysis within each genetic group adjusting for age, sex, and scanner type 
(as there were significant differences between groups for each of these, 
Table 1), as well as total intracranial volume, with correction for mul-
tiple comparisons using the Benjamini & Hochberg method (Benjamini 
and Hochberg, 1995) using p = 0.05 for false discovery rate. The 
correction was performed separately for the genetic groups (MAPT, 
GRN, C9orf72), while considering the number of comparisons within 
each of the main regions (cortical, cerebellum, brainstem, thalamus, 
hypothalamus, amygdala, hippocampus, and other subcortical 
structures). 
3. Results 
3.1. Total brain and cortical volumes 
The total brain volume was significantly smaller in all genetic groups 
with CDR ≥ 1 when compared to controls (8–10% volumetric difference, 
p < 0.0005). However, it was also significantly smaller in C9orf72 
expansion carriers at CDR 0 and 0.5 (1–3%, p ≤ 0.004) (Supplementary 
Table 1, Supplementary Fig. 1). 
C9orf72 expansion carriers with a CDR ≥ 1 showed significantly 
smaller volumes than controls in all cortical regions, with the largest 
differences in the anterior and posterior insula (24%) (Supplementary 
Table 1, Supplementary Fig. 2). These two regions, together with the 
DLPFC, motor, dorsolateral temporal, lateral parietal and occipital 
cortex, were also significantly smaller in the C9orf72 expansion carriers 
with CDR 0 and 0.5 (2–7%, p ≤ 0.006). The temporal pole was signifi-
cantly smaller than controls in those scoring 0.5 (6%, p = 0.004), while 
the orbitofrontal, posterior cingulate, sensory and medial parietal cortex 
were significantly smaller in those scoring 0 (1–4%, p ≤ 0.028), but 
these differences did not reach statistical significance in those scoring 
0.5 (Supplementary Table 1, Supplementary Fig. 2). 
MAPT mutation carriers with CDR ≥ 1 showed smaller volumes than 
controls in the temporal regions (32% in the temporal pole), insula 
(29–30%) and anterior cingulate (12%) (p < 0.0005) (Supplementary 
Table 1, Supplementary Fig. 2). The dorsolateral temporal cortex was 
smaller in the CDR 0.5 group (17%, p = 0.003). No difference was found 
in the CDR 0 group. 
GRN mutation carriers with CDR ≥ 1 showed smaller volumes in all 
regions (6–26%, p ≤ 0.012) except the sensory cortex, with the anterior 
insula being the region with smallest volume (26%, p < 0.0005). GRN 
mutation carriers with CDR 0.5 also showed smaller DLPFC and anterior 
insula volumes than controls (5–6%, p ≤ 0.013) (Supplementary 
Table 1, Supplementary Fig. 2). No difference was found in the CDR 
0 group. 
3.2. Basal ganglia 
Among the basal ganglia, the putamen was significantly smaller 
across all C9orf72 stages (1–17%, p ≤ 0.0006) (Supplementary Table 1, 
Fig. 2A), and in the MAPT and GRN mutation carriers with CDR ≥ 1 
(17%, p < 0.0005). C9orf72 expansion carriers with CDR 0.5 and ≥ 1 
showed smaller globus pallidus (6–16%, p ≤ 0.003). MAPT mutation 
carriers with CDR ≥ 1 showed smaller volumes than controls in the 
nucleus accumbens (11%), and globus pallidus (14%), whilst GRN mu-
tation carriers scoring ≥ 1 showed smaller caudate (5%, p = 0.011) and 
globus pallidus (12%, p < 0.0005). No differences were found for the 
MAPT and GRN mutation carriers in the CDR 0 or 0.5 groups. 
3.3. Basal forebrain 
Changes in the basal forebrain were only seen in MAPT mutation 
carriers (Supplementary Table 1, Fig. 2A), and only at the CDR ≥ 1 stage 
(15% smaller than controls, p < 0.0005). 
3.4. Amygdala 
All amygdalar regions were significantly smaller than controls for all 
mutation carriers with CDR ≥ 1 (p < 0.0005), with the MAPT group 
showing the largest differences, particularly in the superficial and 
Table 1 
Demographic and clinical characteristic of the cohort divided by genetic group and CDR®+NACC FTLD global scores. Abbreviations: N/A not applicable, FTD 
frontotemporal dementia, bvFTD behavioural variant FTD, PPA primary progressive aphasia, NOS not otherwise specified, CBS corticobasal syndrome, PSP progressive 
supranuclear palsy, AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis.   
Non- 
carriers 
C9orf72 expansion carriers MAPT mutation carriers GRN mutation carriers 
CDR®+NACC FTLD global 
score  
0 0.5 ≥1 0 0.5 ≥1 0 0.5 ≥1 
N 298 107 32 63 47 13 20 125 30 43 






























Scanners [Siemens Trio/ 
Siemens Skyra/Siemens 
Prisma/Philips Achieva/ 

















Clinical phenotype N/A N/A N/A 49 bvFTD, 6 FTD- 
ALS, 2 ALS, 2 PPA, 1 
PSP, 2 Dementia- 
NOS, 1 Other 




N/A N/A 24 bvFTD, 
17 PPA, 1 
CBS, 1 AD  
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accessory basal regions (44%) as well as the lateral regions (36%) 
(Supplementary Table 1, Figure 2B). All regions were significantly 
smaller in C9orf72 expansion carriers at CDR 0, and in MAPT mutation 
carriers with CDR 0.5, with smaller volumes at CDR 0 in the superficial 
and accessory basal nuclei (2–4%, p ≤ 0.034) (Supplementary Table 1, 
Figure 2B). GRN mutation carriers with CDR 0 or 0.5 did not show any 
significant differences from controls. 
3.5. Hippocampus 
All hippocampal regions were significantly smaller than controls for 
all mutation carriers with CDR ≥ 1 (p < 0.0005), with MAPT mutation 
carriers being the genetic group with the largest differences (all above 
30%) (Supplementary Table 1, Figure 2C). Differences were also seen in 
all regions in MAPT mutation carriers with CDR 0.5 (6–11%, p ≤ 0.019), 
and in the subiculum, presubiculum and tail (3–4%, p ≤ 0.020) in MAPT 
mutation carriers with CDR 0. In C9orf72 expansion carriers with CDR 
0 there were significantly smaller volumes than controls in all regions 
except the tail and the subiculum (2–3%, p ≤ 0.015). The presubiculum 
was the only region significantly smaller in GRN mutation carriers with 
CDR 0.5 (8%, p = 0.016) with no significant differences at CDR 0. 
3.6. Thalamus 
C9orf72 expansion carriers showed significantly smaller thalamic 
regions in all stages, with the only exception being the ventromedial 
nucleus (which only became significant at CDR stage ≥ 1) and the 
ventral posterolateral nucleus, which did not quite reach statistical 
Fig. 1. Regions of interest used in the anal-
ysis. Abbreviations. Cortical: VMPFC 
ventromedial prefrontal, TP temporal pole, 
MT medial temporal, AC anterior cingulate, 
PC posterior cingulate, MOT motor, S sen-
sory, MP medial parietal, OCC occipital, 
DLPFC dorsolateral prefrontal, OF orbito-
frontal, AI anterior insular, PI posterior 
insular, DLT dorsolateral temporal, LP lateral 
parietal; Basal ganglia and Basal forebrain: 
GP pallidum, CAU caudate, PUT putamen, BF 
basal forebrain, NA nucleus accumbens; 
Brainstem: SCP superior cerebellar peduncle, 
MB midbrain, ME medulla; Cerebellum: VIIA 
– CI lobule VIIA – Crus I, VIIA – CII lobule 
VIIA – Crus II, FN fastigial nucleus, IN 
interposed nucleus, DN dentate nucleus; 
Amygdala: CAT cortico-amygdaloid transi-
tion area, Sup superficial nuclei, AB acces-
sory basal nucleus; Hippocampus: DG 
dentate gyrus, CA cornu ammonis; Thal-
amus: AV anteroventral, VA ventral anterior, 
LD laterodorsal, VLa ventral lateral anterior, 
MD mediodorsal, LP lateral posterior, VLp 
ventral lateral posterior, VPL ventral 
posterolateral, VM ventromedial, LGN lateral 
geniculate nucleus, MGN medial geniculate 
nucleus; Hypothalamus: as anterior superior, 
ai anterior inferior, s-tub superior tuberal, i- 
tub inferior tuberal, pos posterior.   
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Fig. 2. A–G. Plots representing the means and 
standard error bars for regional brain volumes 
for each of the stages in C9orf72, MAPT and 
GRN mutation carriers. Volumes as expressed 
as % the mean volumes in controls (y axis). * 
indicates a significant difference from controls 
after correcting for multiple comparisons. 
Abbreviations: Amygdala: CAT cortico- 
amygdaloid transition area; Thalamus: LD 
laterodorsal, VLa ventral lateral anterior, VLp 
ventral lateral posterior, VPL ventral postero-
lateral, LGN lateral geniculate nucleus, MGN 
medial geniculate nucleus; Hypothalamus: AI 
anterior inferior, AS anterior superior, I-TUB 
inferior tuberal, S-TUB superior tuberal; 
Brainstem: SCP superior cerebellar peduncle.   
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significance at CDR 0.5. The most affected regions at CDR 0 were the LD 
(13%), LGN (10%) and pulvinar (9%) (p < 0.0005) (Supplementary 
Table 1, Figure 2D). MAPT mutation carriers with CDR ≥ 1 showed 
significantly smaller volumes in all regions except LGN, with the main 
differences located in the MD, midline and LD regions (22–26%, p <
0.0005) but no differences at earlier stages. GRN mutation carriers also 
only showed significantly smaller regions at CDR ≥ 1, with the main 
differences located in the MD and midline regions (31%, p < 0.0005), 
followed by the anteroventral and LD (21–25%, p < 0.0005). No dif-
ferences were found in the LGN and MGN. 
3.7. Hypothalamus 
All regions were significantly smaller than controls for all mutation 
carriers with CDR ≥ 1 (p < 0.0005), except for the i-tub regions for 
C9orf72 and GRN mutation carriers. In the CDR ≥ 1 group MAPT mu-
tation carriers had the smallest volumes, with differences above 29% in 
the posterior and anterior regions (Supplementary Table 1, Figure 2E). 
C9orf72 expansion carriers were the only ones showing early differ-
ences, with the CDR 0.5 group showing smaller volumes than controls in 
the anterior superior and s-tub regions (5–7%, p ≤ 0.017), and the CDR 
0 group showing smaller volumes than controls in the s-tub region (1%, 
p = 0.008). 
3.8. Cerebellum 
C9orf72 and GRN mutation carriers with CDR ≥ 1 had smaller vol-
umes than controls in the lobules VIIa-Crus II (13%), VIIb (11–12%) and 
VIIIa (8–10%) (p ≤ 0.001), with C9orf72 expansion carriers also 
showing significant differences in lobules VI (12%), VIIIb (14%), vermis 
(7%) and the dentate nucleus (7%) (p ≤ 0.007). In addition, the C9orf72 
expansion carriers were the only group with significantly smaller vol-
umes at CDR 0 (lobules VIIa-Crus II and VIIb, 2–3% p ≤ 0.011) (Sup-
plementary Table 1, Figure 2F). No significant difference was found in 
the MAPT group. 
3.9. Brainstem 
GRN mutation carriers with CDR ≥ 1 showed smaller volumes in the 
superior cerebellar peduncle (5%, p = 0.011), midbrain and pons 
(7–8%, p < 0.0005), while MAPT mutation carriers scoring ≥ 1 showed 
smaller volumes in the midbrain (9%, p < 0.0005) (Supplementary 
Table 1, Figure 2G). No difference was detected in those with CDR 0 or 
0.5, or in C9orf72 expansion carriers at any stage. 
Fig. 3 summarizes the sequential pattern of neuroanatomical 
involvement for each of the genetic groups, by indicating at which stage 
each region resulted significantly smaller than controls. 
4. Discussion 
In this study we have defined the pattern of involvement in subcor-
tical brain regions and specific nuclei in genetic frontotemporal de-
mentia. We have identified gene-specific changes in asymptomatic and 
prodromal stages through to fully symptomatic stages in C9orf72, MAPT 
and GRN mutation carriers. By looking at specific regions, in a large 
cohort of mutation carriers, we were able to identify small changes that 
occurs very early on in all genetic groups, which might go undetected 
when looking at the whole brain or at large regions. 
The first brain regions showing differences from controls in C9orf72 
expansion carriers without any detectable clinical symptoms were the 
thalamic regions (the pulvinar, LD and LGN in particular), the putamen, 
the CA regions with the dentate gyrus and the presubiculum, all the 
amygdalar regions, the s-tub region in the hypothalamus, the lobule 
VIIa-Crus II and VIIb of the cerebellum as well as several cortical regions. 
By the time C9orf72 expansion carriers reach the symptomatic phase, 
nearly all the regions in the brain become affected, with the exception of 
the caudate, nucleus accumbens, basal forebrain, brainstem, and the 
anterior and inferior cerebellum and the i-tub region of the hypothala-
mus. These results are in line with previous studies showing widespread 
involvement of the brain in C9orf72-associated FTD, well beyond the 
classical frontal and temporal regions of FTD (Rohrer et al., 2015; Cash 
et al., 2018; Bertrand et al., 2018; Lee et al., 2017). 
Among the thalamic regions, the pulvinar and LGN were particularly 
affected in C9orf72 expansion carriers, which is in line with previous 
Fig. 3. Sequential pattern of neuroanatomical involvement in C9orf72, MAPT and GRN. The colour map indicates the stage defined by CDR®+NACC FTLD global 
scores when the specific region of interest becomes involved, as significantly smaller than controls. 
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research in both symptomatic and presymptomatic carriers (Bocchetta 
et al., 2020; Lee et al., 2017) and with the pathological accumulation of 
TDP-43 and dipeptide repeat proteins in those regions (Vatsavayai et al., 
2016; Yang et al., 2017) Atrophy in these regions is linked to halluci-
nations and other psychotic symptoms as well as the altered processing 
of pain, features seen more commonly in C9orf72 expansion carriers 
than in other forms of FTD (Convery et al., 2020; Ducharme et al., 2017; 
Fletcher et al., 2015; Kertesz et al., 2013). 
Interestingly, the regions affected early in the cerebellum (lobule 
VIIa-Crus II and VIIb) are connected via the dentate nuclei to the ventral 
anterior and ventrolateral nuclei of the thalamus and from here to the 
DLPFC to regulate cognitive functions, and in particular goal-directed 
complex behaviours (Makris et al., 2003; D’Angelo and Casali, 2013; 
Palesi et al., 2015). The cerebellum is also connected via the anterior 
and ventral lateral posterior thalamic regions to the basal ganglia and 
the parietal and motor cortex (Palesi et al., 2015); all regions affected 
early in C9orf72-associated FTD. Dipeptide repeat proteins are also 
typical and abundant in the cerebellar cortex (Mackenzie and Neumann, 
2016). 
The most affected regions within the hippocampus and amygdala are 
among the ones previously shown to be atrophic in symptomatic 
C9orf72 expansion carriers (Bocchetta et al., 2018, 2019) and connected 
to the temporal and posterior cortex (de Flores et al., 2017). The CA 
regions are abundant of dipeptide repeat proteins, with or without TDP- 
43 deposition (Mann and Snowden, 2017). 
C9orf72 expansion carriers at CDR 0 showed reduced volumes in the 
s-tub region of the hypothalamus and later on in the anterior and pos-
terior hypothalamus, leaving the i-tub as the only spared region as 
previously reported (Bocchetta et al., 2015). The s-tub region includes 
the dorso-medial nucleus and lateral hypothalamic area, which regulate 
appetite and contain neuropeptide-expressing neurons and neuropep-
tide receptors (Parker and Bloom, 2012). Similarly, volume loss in the 
posterior hypothalamus and the presence of TDP-43 pathology have 
been linked to the development of abnormal eating behaviours, typical 
symptoms of bvFTD (Bocchetta et al., 2015; Piguet et al., 2011). 
In MAPT mutation carriers, the only regions affected at CDR 0 were 
the superficial and accessory basal regions of the amygdala, and the 
subiculum, presubiculum and hippocampal tail. Such early differences 
in the amygdala could not be detected when looking at its volume as a 
whole, which only became significantly affected at a later stage. MAPT 
mutation carriers at CDR 0.5 additionally showed smaller volumes in the 
dorsolateral temporal cortex and in all the other hippocampal and 
amygdalar regions. Overall, the more medial regions of the amygdala 
(particularly the superficial, accessory basal and basal and paralaminar) 
tend to be affected more than the lateral regions. They are connected to 
key limbic regions and likely related to the development of symptoms 
associated with abnormal reward and emotional processing. These re-
sults are in line with previous in vivo studies on symptomatic mutation 
carriers (Bocchetta et al., 2018, 2019) and with pathological studies: tau 
deposition is extensively found in the hippocampus and other limbic 
structures in MAPT mutation carriers (Ghetti et al., 2015). 
By the time MAPT mutation carriers are fully symptomatic, we find 
lower volumes in the other key regions of the limbic system, such as the 
insula, anterior cingulate, mediotemporal cortex, nucleus accumbens 
and basal forebrain. This latter structure, the basal forebrain, was only 
affected in the MAPT genetic group, as previously reported (Convery 
et al., 2020). Other regions affected in this group include the midbrain, 
which forms part of a network that regulates emotion perception with 
the thalamus and amygdala (Liddell et al., 2005). All regions in the 
hypothalamus were also affected, although mainly in the superior and 
posterior regions as previously reported in a smaller cohort (Bocchetta 
et al., 2015). Interestingly, the posterior region includes the mammillary 
bodies, connected via the fornix to the amygdala and hippocampus. 
Among the thalamic regions, the MD was the most affected, as previ-
ously reported (Bocchetta et al., 2020): this region is connected to brain 
regions within the limbic network and plays a role in emotional and 
behavioural regulation, as well as executive function. This sequence of 
regional involvement and the localisation in the temporal lobe is in line 
with what has been reported in other studies in MAPT mutation carriers 
(Rohrer et al., 2015; Cash et al., 2018; Whitwell et al., 2012; Olney et al., 
2020). The vermis of the cerebellum, another important part of the 
limbic system, was not affected, in contrast with what was found by 
another study (Bocchetta et al., 2016). This could be due to the different 
way of classifying the symptomatic mutation carriers, and the presence 
of different scanner types and sample characteristics. However, the fact 
that the cerebellum was overall not affected in MAPT-associated FTD is 
in line with other studies (Rohrer et al., 2015). 
GRN mutation carriers only showed significant atrophy at the CDR 
0.5 stage – this was mainly cortical, affecting the DLPFC, and anterior 
insula, but there was also subcortical involvement of the presubiculum, 
a hippocampal region connected to the basal ganglia, frontal and pari-
etal cortex, areas which are typically atrophic in GRN, as found here at 
the symptomatic stages and in other studies (Rohrer et al., 2015; Cash 
et al., 2018; Olney et al., 2020); and which typically show TDP-43 
accumulation (Mann and Snowden, 2017). 
Previously described as spared in GRN mutation carriers (Bocchetta 
et al., 2016); we found here that lobule VIIa-Crus II, VIIb and VIIIa are 
affected later in the disease. These regions are connected, via the thal-
amus, to the DLPFC and primary sensorimotor cortex (Makris et al., 
2003). Within the brainstem, the midbrain, pons, and superior cere-
bellar peduncle were atrophic, as previously found (Rohrer et al., 2010). 
The role of the brainstem in FTD is not yet fully understood, but TDP-43 
pathology has been found previously in several nuclei of the midbrain 
and pons (Grinberg et al., 2011). When symptoms were clearly present 
in GRN mutation carriers, all the hypothalamic regions were also smaller 
than in controls, with the exception of the i-tub (similarly to the C9orf72 
group). This region includes the arcuate nucleus, an important target for 
metabolic and hormonal signals (Parker and Bloom, 2012). Interest-
ingly, in a previous histological study (and consistent with our findings), 
TDP-43 inclusions were not found in this region, but were abundant in 
the anterior, superior and posterior region of the hypothalamus 
(Cykowski et al., 2016). 
C9orf72 expansion carriers showed by far the earliest and most 
widespread changes in the brain, compared to MAPT and GRN mutation 
carriers. Even the total brain volume was lower in C9orf72 expansion 
carriers at CDR 0 whilst only being affected at the fully symptomatic 
stage in MAPT and GRN mutation carriers. This result was found pre-
viously (Rohrer et al., 2015) and could suggest that C9orf72-associated 
FTD might be associated with a long and slow process of neuro-
degeneration which could start many decades before the onset of clinical 
symptoms, as also suggested by Staffaroni et al (Staffaroni et al., 2020). 
GRN mutation carriers instead might have a more rapid process which 
occurs later and closer to symptom onset (Jiskoot et al., 2019). Longi-
tudinal studies, such as in Staffaroni et al (Staffaroni et al., 2020) and 
Whitwell et al (Whitwell et al., 2015), looking at the atrophy rates in the 
different disease stages could potentially provide a definite answer to 
whether this is the case. 
This study has some limitations. Some of the nuclei are very small 
and we grouped them into combined regions, or clusters of nuclei. In the 
future, this could be addressed by imaging at higher field strengths (e.g. 
7 T), enabling higher spatial resolution. There were differences in age, 
sex and scanner type for some of the groups, which we have taken into 
account by including these variables as covariates, although this cannot 
completely exclude their impact. The CDR 0.5 is smaller than the other 
groups, and is likely to be heterogeneous including both people who are 
truly in a mild prodromal stage, and others that score 0.5 due to 
‘questionable’ symptoms that might instead be related to affective 
symptoms during the at-risk period. 
By looking at in vivo regional volumetry, we have shown here a 
differential pattern of subcortical changes across severity stages in 
C9orf72, MAPT and GRN mutation carriers. By looking at a wide range of 
specific brain regions, for the first time we were able to measure small 
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changes that occur in localized regions in the early stages of genetic FTD. 
These results suggest that these changes may be used as markers of 
neurodegeneration in future trials even during preclinical and prodro-
mal periods. Further longitudinal studies, including multimodal imaging 
looking at brain connectivity networks and including correlations with 
cognitive and other biomarkers, will be vital to investigate these results 
further. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Acknowledgments 
We thank the research participants for their contribution to the 
study. The Dementia Research Centre is supported by Alzheimer’s 
Research UK, Alzheimer’s Society, Brain Research UK, and The Wolfson 
Foundation. This work was supported by the National Institute for 
Health Research (NIHR) Queen Square Dementia Biomedical Research 
Unit and the University College London Hospitals Biomedical Research 
Centre, the Leonard Wolfson Experimental Neurology Centre (LWENC) 
Clinical Research Facility, and the UK Dementia Research Institute, 
which receives its funding from UK DRI Ltd, funded by the UK Medical 
Research Council, Alzheimer’s Society and Alzheimer’s Research UK. 
This work was also supported by the MRC UK GENFI grant (MR/ 
M023664/1), the Italian Ministry of Health (CoEN015 and Ricerca 
Corrente), the Canadian Institutes of Health Research as part of a Cen-
tres of Excellence in Neurodegeneration grant, a Canadian Institutes of 
Health Research operating grant, the Alzheimer’s Society grant (AS-PG- 
16-007), the Bluefield Project and the JPND GENFI-PROX grant (2019- 
02248). MB is supported by a Fellowship award from the Alzheimer’s 
Society, UK (AS-JF-19a-004-517). MB’s work was also supported by the 
UK Dementia Research Institute which receives its funding from DRI Ltd, 
funded by the UK Medical Research Council, Alzheimer’s Society and 
Alzheimer’s Research UK. MB acknowledges the support of NVIDIA 
Corporation with the donation of the Titan V GPU used for part of the 
analyses in this research. JDR is an MRC Clinician Scientist (MR/ 
M008525/1) and has received funding from the NIHR Rare Diseases 
Translational Research Collaboration (BRC149/NS/MH), the Bluefield 
Project and the Association for Frontotemporal Degeneration. JEI is 
supported by the European Research Council (Starting Grant 677697, 
project BUNGEE-TOOLS), Alzheimer’s Research UK (ARUK- 
IRG2019A003) and NIH 1RF1MH123195-01. JBR is funded by the 
Wellcome Trust (103838) and the National Institute for Health Research 
Cambridge Biomedical Research Centre. This work was funded by the 
Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) 
under Germany’s Excellence Strategy within the framework of the 
Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 
390857198). Several authors of this publication (JCvS, MS, RSV, AD, 
MO, JDR) are members of the European Reference Network for Rare 
Neurological Diseases (ERN-RND) - Project ID No 739510. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.nicl.2021.102646. 
References 
Warren, J.D., Rohrer, J.D., Rossor, M.N., 2013. Clinical review. Frontotemporal 
dementia. BMJ 347 (aug12 3) f4827.  
Chen, Q., Kantarci, K., 2020. Imaging Biomarkers for Neurodegeneration in 
Presymptomatic Familial Frontotemporal Lobar Degeneration. Front. Neurol. 11, 80. 
Rohrer, J.D., Nicholas, J.M., Cash, D.M., van Swieten, J., Dopper, E., Jiskoot, L., van 
Minkelen, R., Rombouts, S.A., Cardoso, M.J., Clegg, S., Espak, M., Mead, S., 
Thomas, D.L., De Vita, E., Masellis, M., Black, S.E., Freedman, M., Keren, R., 
MacIntosh, B.J., Rogaeva, E., Tang-Wai, D., Tartaglia, M.C., Laforce, R., 
Tagliavini, F., Tiraboschi, P., Redaelli, V., Prioni, S., Grisoli, M., Borroni, B., 
Padovani, A., Galimberti, D., Scarpini, E., Arighi, A., Fumagalli, G., Rowe, J.B., 
Coyle-Gilchrist, I., Graff, C., Fallström, M., Jelic, V., Ståhlbom, A.K., Andersson, C., 
Thonberg, H., Lilius, L., Frisoni, G.B., Binetti, G., Pievani, M., Bocchetta, M., 
Benussi, L., Ghidoni, R., Finger, E., Sorbi, S., Nacmias, B., Lombardi, G., Polito, C., 
Warren, J.D., Ourselin, S., Fox, N.C., Rossor, M.N., 2015. Presymptomatic cognitive 
and neuroanatomical changes in genetic frontotemporal dementia in the Genetic 
Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet 
Neurol. 14 (3), 253–262. 
Cash, D.M., Bocchetta, M., Thomas, D., et al., 2018. Patterns of grey matter atrophy in 
genetic frontotemporal dementia: results from the GENFI study. Neurobiol. Aging 
62, 191–196. 
Bocchetta, M., Cardoso, M.J., Cash, D.M., Ourselin, S., Warren, J.D., Rohrer, J.D., 2016. 
Patterns of regional cerebellar atrophy in genetic frontotemporal dementia. 
Neuroimage Clin. 11, 287–290. 
Bocchetta, M., Iglesias, J.E., Scelsi, M.A., Cash, D.M., Cardoso, M.J., Modat, M., 
Altmann, A., Ourselin, S., Warren, J.D., Rohrer, J.D., Sala-Llonch, R., 2018. 
Hippocampal subfield volumetry: differential pattern of atrophy in different forms of 
genetic frontotemporal dementia. J. Alzheimer’s Dis. 64 (2), 497–504. 
Bocchetta, M., Iglesias, J.E., Cash, D.M., Warren, J.D., Rohrer, J.D., 2019. Amygdala 
subnuclei are differentially affected in the different genetic and pathological forms of 
frontotemporal dementia. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease 
Monitoring. 11 (1), 136–141. 
Bocchetta, M., Iglesias, J.E., Neason, M., Cash, D.M., Warren, J.D., Rohrer, J.D., 2020. 
Thalamic nuclei in frontotemporal dementia: mediodorsal nucleus involvement is 
universal but pulvinar atrophy is unique to C9orf72. Hum. Brain Mapp. 41 (4), 
1006–1016. 
Miyagawa, T., Brushaber, D., Syrjanen, J., Kremers, W., Fields, J., Forsberg, L.K., 
Heuer, H.W., Knopman, D., Kornak, J., Boxer, A., Rosen, H.J., Boeve, B.F., 
Appleby, B., Bordelon, Y., Bove, J., Brannelly, P., Caso, C., Coppola, G., Dever, R., 
Dheel, C., Dickerson, B., Dickinson, S., Dominguez, S., Domoto-Reilly, K., Faber, K., 
Ferrell, J., Fishman, A., Fong, J., Foroud, T., Gavrilova, R., Gearhart, D., 
Ghazanfari, B., Ghoshal, N., Goldman, J.S., Graff-Radford, J., Graff-Radford, N., 
Grant, I., Grossman, M., Haley, D., Hsiung, R., Huey, E., Irwin, D., Jones, D., 
Jones, L., Kantarci, K., Karydas, A., Kaufer, D., Kerwin, D., Kraft, R., Kramer, J., 
Kukull, W., Litvan, I., Lucente, D., Lungu, C., Mackenzie, I., Maldonado, M., 
Manoochehri, M., McGinnis, S., McKinley, E., Mendez, M.F., Miller, B., Multani, N., 
Onyike, C., Padmanabhan, J., Pantelyat, A., Pearlman, R., Petrucelli, L., Potter, M., 
Rademakers, R., Ramos, E.M., Rankin, K., Rascovsky, K., Roberson, E.D., 
Rogalski, E., Sengdy, P., Shaw, L., Tartaglia, M.C., Tatton, N., Taylor, J., Toga, A., 
Trojanowski, J.Q., Wang, P., Weintraub, S., Wong, B., Wszolek, Z., 2020. Utility of 
the global CDR® plus NACC FTLD rating and development of scoring rules: Data 
from the ARTFL/LEFFTDS Consortium. Alzheimer’s & dementia: the journal of the 
Alzheimer’s Association. 16 (1), 106–117. 
Cardoso, M.J., Modat, M., Wolz, R., Melbourne, A., Cash, D., Rueckert, D., Ourselin, S., 
2015. Geodesic information flows: spatially-variant graphs and their application to 
segmentation and fusion. IEEE TMI 34 (9), 1976–1988. https://doi.org/10.1109/ 
TMI.4210.1109/TMI.2015.2418298. 
Iglesias, J.E., Augustinack, J.C., Nguyen, K., Player, C.M., Player, A., Wright, M., Roy, N., 
Frosch, M.P., McKee, A.C., Wald, L.L., Fischl, B., Van Leemput, K., 2015. 
A computational atlas of the hippocampal formation using ex vivo, ultra-high 
resolution MRI: Application to adaptive segmentation of in vivo MRI. Neuroimage. 
115, 117–137. 
Iglesias, J.E., Van Leemput, K., Bhatt, P., Casillas, C., Dutt, S., Schuff, N., Truran- 
Sacrey, D., Boxer, A., Fischl, B., 2015. Bayesian segmentation of brainstem structures 
in MRI. Neuroimage. 113, 184–195. 
Iglesias, J.E., Insausti, R., Lerma-Usabiaga, G., Bocchetta, M., Van Leemput, K., Greve, D. 
N., van der Kouwe, A., Fischl, B., Caballero-Gaudes, C., Paz-Alonso, P.M., 2018. 
A probabilistic atlas of the human thalamic nuclei combining ex vivo MRI and 
histology. Neuroimage. 183, 314–326. 
Saygin, Z.M., Kliemann, D., Iglesias, J.E., van der Kouwe, A.J.W., Boyd, E., Reuter, M., 
Stevens, A., Van Leemput, K., McKee, A., Frosch, M.P., Fischl, B., Augustinack, J.C., 
2017. High-resolution magnetic resonance imaging reveals nuclei of the human 
amygdala: manual segmentation to automatic atlas. Neuroimage. 155, 370–382. 
Bocchetta, M., Iglesias, J.E., Chelban, V., Jabbari, E., Lamb, R., Russell, L.L., Greaves, C. 
V., Neason, M., Cash, D.M., Thomas, D.L., Warren, J.D., Woodside, J., Houlden, H., 
Morris, H.R., Rohrer, J.D., 2020a. Automated brainstem segmentation detects 
differential involvement in atypical parkinsonian syndromes. J. Mov. Disord. 13 (1), 
39–46. 
Billot, B., Bocchetta, M., Todd, E., Dalca, A.V., Rohrer, J.D., Iglesias, J.E., 2020. 
Automated segmentation of the Hypothalamus and associated subunits in brain MRI. 
Neuroimage. 223, 117287. https://doi.org/10.1016/j.neuroimage.2020.117287. 
Diedrichsen, J., Balsters, J.H., Flavell, J., Cussans, E., Ramnani, N., 2009. A probabilistic 
MR atlas of the human cerebellum. NeuroImage. 46 (1), 39–46. 
Diedrichsen, J., Maderwald, S., Küper, M., Thürling, M., Rabe, K., Gizewski, E.R., 
Ladd, M.E., Timmann, D., 2011. Imaging the deep cerebellar nuclei: a probabilistic 
atlas and normalization procedure. NeuroImage 54 (3), 1786–1794. 
Malone, I.B., Leung, K.K., Clegg, S., Barnes, J., Whitwell, J.L., Ashburner, J., Fox, N.C., 
Ridgway, G.R., 2015. Accurate automatic estimation of total intracranial volume: a 
nuisance variable with less nuisance. Neuroimage. 104, 366–372. 
Benjamini, Y., Hochberg, Y., 1995. Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. J. Roy. Stat. Soc.: Ser. B (Methodol.) 57 (1), 
289–300. 
M. Bocchetta et al.                                                                                                                                                                                                                             
NeuroImage: Clinical 30 (2021) 102646
9
Bertrand, A., Wen, J., Rinaldi, D., Houot, M., Sayah, S., Camuzat, A., Fournier, C., 
Fontanella, S., Routier, A., Couratier, P., Pasquier, F., Habert, M.-O., Hannequin, D., 
Martinaud, O., Caroppo, P., Levy, R., Dubois, B., Brice, A., Durrleman, S., Colliot, O., 
Le Ber, I., 2018. Early Cognitive, Structural, and Microstructural Changes in 
Presymptomatic C9orf72 Carriers Younger Than 40 Years. JAMA Neurol. 75 (2), 
236. https://doi.org/10.1001/jamaneurol.2017.4266. 
Lee, S.E., Sias, A.C., Mandelli, M.L., Brown, J.A., Brown, A.B., Khazenzon, A.M., 
Vidovszky, A.A., Zanto, T.P., Karydas, A.M., Pribadi, M., Dokuru, D., Coppola, G., 
Geschwind, D.H., Rademakers, R., Gorno-Tempini, M.L., Rosen, H.J., Miller, B.L., 
Seeley, W.W., 2017. Network degeneration and dysfunction in presymptomatic 
C9ORF72 expansion carriers. Neuroimage Clin. 14, 286–297. 
Vatsavayai, S.C., Yoon, S.J., Gardner, R.C., Gendron, T.F., Vargas, J.N.S., Trujillo, A., 
Pribadi, M., Phillips, J.J., Gaus, S.E., Hixson, J.D., Garcia, P.A., Rabinovici, G.D., 
Coppola, G., Geschwind, D.H., Petrucelli, L., Miller, B.L., Seeley, W.W., 2016. Timing 
and significance of pathological features in C9orf72 expansion-associated 
frontotemporal dementia. Brain. 139 (12), 3202–3216. 
Yang, Y., Halliday, G.M., Hodges, J.R., Tan, R.H., Whitwell, J., 2017. von Economo 
Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal 
Dementia Cases with and without a C9ORF72 Repeat Expansion. J. Alzheimers Dis. 
58 (3), 701–709. 
Convery, R.S., Bocchetta, M., Greaves, C.V., Moore, K.M., Cash, D.M., Van Swieten, J., 
Moreno, F., Sánchez-Valle, R., Borroni, B., Laforce Jr, R., Masellis, M., Tartaglia, M. 
C., Graff, C., Galimberti, D., Rowe, J.B., Finger, E., Synofzik, M., Vandenberghe, R., 
de Mendonca, A., Tagliavini, F., Santana, I., Ducharme, S., Butler, C., Gerhard, A., 
Levin, J., Danek, A., Otto, M., Warren, J.D., Rohrer, J.D., 2020. Abnormal pain 
perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion 
carriers in the GENFI cohort. J. Neurol. Neurosurg. Psychiatry 91 (12), 1325–1328. 
https://doi.org/10.1136/jnnp-2020-323279. 
Ducharme, S., Bajestan, S., Dickerson, B.C., Voon, V., 2017. Psychiatric presentations of 
C9orf72 mutation: What are the diagnostic implica- tions for clinicians? 
J. Neuropsychiatry Clin. Neurosci. 29 (3), 195–205. 
Fletcher, P.D., Downey, L.E., Golden, H.L., Clark, C.N., Slattery, C.F., Paterson, R.W., 
Rohrer, J.D., Schott, J.M., Rossor, M.N., Warren, J.D., 2015. Pain and temperature 
processing in dementia: A clinical and neuroanatomical analysis. Brain 138 (11), 
3360–3372. 
Kertesz A, Ang LC, Jesso S, et al. Psychosis and hallucinations in frontotemporal 
dementia with the C9ORF72 mutation: a detailed clinical cohort. Cogn Behav 
Neurol. 2013;26(3):146-54. 
Makris, N., Hodge, S.M., Haselgrove, C., Kennedy, D.N., Dale, A., Fischl, B., Rosen, B.R., 
Harris, G., Caviness, V.S., Schmahmann, J.D., 2003. Human cerebellum: surface- 
assisted cortical parcellation and volumetry with magnetic resonance imaging. 
J Cogn Neurosci. 15 (4), 584–599. 
D’Angelo, E., Casali, S., 2013. Seeking a unified framework for cerebellar function and 
dysfunction: from circuit operations to cognition. Front. Neural Circuits 10 (6), 116. 
Palesi, F., Tournier, J.-D., Calamante, F., Muhlert, N., Castellazzi, G., Chard, D., 
D’Angelo, E., Wheeler-Kingshott, C.A.M., 2015. Contralateral cerebello-thalamo- 
cortical pathways with prominent involvement of associative areas in humans in 
vivo. Brain Struct. Funct. 220 (6), 3369–3384. 
Mackenzie, I.R., Neumann, M., 2016. Molecular neuropathology of frontotemporal 
dementia: insights into disease mechanisms from postmortem studies. J. Neurochem. 
138 (Suppl 1), 54–70. 
de Flores, R., Mutlu, J., Bejanin, A., Gonneaud, J., Landeau, B., Tomadesso, C., 
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